BioNexus Gene Lab Corp. (NASDAQ:BGLC) Short Interest Update

BioNexus Gene Lab Corp. (NASDAQ:BGLCGet Free Report) was the target of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 63,600 shares, a growth of 25.7% from the April 30th total of 50,600 shares. Based on an average trading volume of 618,600 shares, the days-to-cover ratio is presently 0.1 days. Approximately 5.4% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut shares of BioNexus Gene Lab to a “strong sell” rating in a report on Friday, May 30th.

Check Out Our Latest Report on BGLC

BioNexus Gene Lab Price Performance

Shares of BGLC stock opened at $3.28 on Thursday. BioNexus Gene Lab has a 12-month low of $2.01 and a 12-month high of $8.40. The firm has a fifty day moving average of $2.84 and a 200-day moving average of $3.12.

BioNexus Gene Lab (NASDAQ:BGLCGet Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.03) EPS for the quarter. BioNexus Gene Lab had a negative return on equity of 9.93% and a negative net margin of 10.17%.

BioNexus Gene Lab Company Profile

(Get Free Report)

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.

Featured Stories

Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.